Psyence Group

About Psyence Group

This author has not yet filled in any details.
So far Psyence Group has created 74 blog entries.
  • PYSENCE_NEWCOURT_FEATURE_2

Psyence Group Announces SEC Effectiveness Of F-4 For Proposed Business Combination Between Subsidiary And NASDAQ Listed Newcourt Acquisitions Corp

2023-11-15T20:55:16+02:00November 15, 2023|Press Releases, Investor Information|

Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), and Newcourt Acquisition Corp  (Nasdaq: NCAC) (“Newcourt”), a special purpose acquisition company today announced that the registration statement on Form F-4 (the “Registration Statement”), filed by Psyence Biomedical Ltd. (“Pubco”) with the Securities and Exchange Commission (“SEC”) was declared effective by the SEC on November 13, 2023.

Read More
  • Psyence Production Expands Capability

Psyence Production Expands Capability

2023-10-30T18:07:59+02:00October 30, 2023|Psychedelic News, Press Releases|

Psyence recently designed a new laboratory at the facility in order to expand its extraction capabilities. The building of the laboratory has since commenced and is expected to be completed in Q4 2023. The expansion fits under the existing building footprint, and once completed, new state-of-the-art extraction equipment will be installed to enhance its current extraction capabilities. There are multiple potential benefits to on-site extraction including increased product shelf life, a more stabilized format for export, and reduced transport costs.

Read More
  • Corporate Updates - Psyence

Psyence Group Corporate Update

2023-08-02T14:35:09+02:00July 12, 2023|Press Releases, Investor Information|

Since Psyence’s corporate update issued in June 2022, the Company has made significant progress in its clinical trial programs and in upgrading its production facility and extraction capabilities. Psyence is executing on its strategy and is pleased to provide an update across the pillars of the business.

Read More
  • Psyence Corporate Update

Psyence Group Announces Closing Of Fourth Round Tranche Of Private Placement And Conversion Of Convertible Debt Note

2023-04-04T06:53:49+02:00April 4, 2023|Press Releases, Investor Information|

Psyence is pleased to announce that it has issued 9,043,038 common shares at a price of CAD$0.12 per common share for gross proceeds of CAD$1,085,164. This brings the total amount the Company has raised pursuant to the previously announced private placement to CAD $3.04 million ("Aggregate Proceeds").

Read More
  • PYSENCE_INGENU_FEATURE_2

Psyence Partners with iNGENū for Palliative Care Clinical Trial in Australia

2023-03-21T17:14:12+02:00March 21, 2023|Press Releases, Investor Information, Psychedelic News|

Psyence Australia Pty Ltd, has partnered with iNGENū Pty Ltd (iNGENū) to conduct Psyence’s previously announced clinical trial in palliative care. iNGENū is an Australian based, globally focused Contract Research Organization (CRO) with extensive experience working in the psychedelic pharmaceutical drug development and clinical research industry.

Read More

Contact Info

General inquiries — info@psyence.com

Media inquiries — media@psyence.com

Investor inquiries — ir@psyence.com

Tel: +1-416-477-1708

Address: 121 Richmond Street West, Penthouse Suite, 1300, Toronto ON M5H2K1, Canada

Sign Up To Our Newsletter

Sign Up To Receive Our Communications

By submitting this form, you are consenting to receive marketing emails from: Psyence Group Inc, 121 Richmond Street West, Penthouse Suite, 1300, Toronto ON M5H2K1 Canada You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.
Go to Top